---
title: "Ulixacaltamide in Essential tremor: References"
description: "Reference list for the formulary evidence report on Ulixacaltamide in Essential tremor. 77 cited documents."
canonical: "https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/references"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ulixacaltamide in Essential tremor: References

<a id="references"></a>

## 5 References

1. [Able (2024a)](https://praxismedicines.com/wp-content/uploads/2024/04/AAN2024_Propranolol_Talk_QRcode.pdf)
2. [Able et al. (2024b)](https://praxismedicines.com/wp-content/uploads/2024/09/MDS2024_E3_StudyDesign_Poster_QRcode.pdf)
3. [Able et al. (2025a)](https://praxismedicines.com/wp-content/uploads/2025/04/AAN2025_HCPxPatient-Survey_Poster_QRcode.pdf)
4. [Able et al. (2025b)](https://index.mirasmart.com/AAN2025/PDFfiles/AAN2025-005726.html)
5. [AlMojel and Fasano (2026)](https://www.sciencedirect.com/science/article/pii/S1353802026007947)
6. [Bhatia et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6530552/)
7. [Brillman et al. (2026a)](https://praxismedicines.com/aan2026-17-002/)
8. [Brillman et al. (2026b)](https://www.aan.com/msa/public/events/abstractdetails/63690)
9. [Brillman et al. (2026c)](https://www.neurology.org/doi/abs/10.1212/WNL.0000000000217731)
10. [ClinicalTrials.gov NCT05021978](https://cdn.clinicaltrials.gov/large-docs/78/NCT05021978/Prot_000.pdf)
11. [ClinicalTrials.gov NCT06087276](https://clinicaltrials.gov/study/NCT06087276)
12. [Dai et al. (2022)](https://jheor.org/article/37307-multiple-comorbidities-psychiatric-disorders-healthcare-resource-utilization-and-costs-among-adults-with-essential-tremor-a-retrospective-observati)
13. [Dash et al. (2026)](https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.70184)
14. [de Cuba et al. (2023)](https://www.mdsabstracts.org/abstract/an-evaluation-of-nbi-827104-for-essential-tremor-results-from-a-randomized-double-blind-placebo-controlled-dose-escalation-crossover-study/)
15. [Elble et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4157921/)
16. [Elble et al. (2024)](https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.29731)
17. [Farmer (2026b)](https://praxismedicines.com/aan2026-pl5-001/)
18. [Farmer et al. (2026a)](https://index.mirasmart.com/AAN2026/PDFfiles/AAN2026-005412.html)
19. [Ferreira et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31046186/)
20. [Gerbasi et al. (2022)](https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2022.891446/full)
21. [Gerbasi et al. (2024)](https://tremorjournal.org/articles/10.5334/tohm.877)
22. [Gerbasi et al. (2025a)](https://tremorjournal.org/articles/10.5334/tohm.1034)
23. [Gerbasi et al. (2025b)](https://tremorjournal.org/articles/10.5334/tohm.1046)
24. [Giroux et al. (2023a)](https://praxismedicines.com/wp-content/uploads/2023/09/Able_IAPRD2023_E1_Readout.pdf)
25. [Giroux et al. (2023b)](https://praxismedicines.com/wp-content/uploads/2023/09/Giroux_MDS2023_E1_MSD_SUBMIT.pdf)
26. [Giroux et al. (2024)](https://www.neurology.org/doi/10.1212/WNL.0000000000205217)
27. [Health Quality Ontario (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5963668/)
28. [Huang et al. (2024)](https://www.nature.com/articles/s41422-024-00959-8)
29. [International Essential Tremor Foundation (2025)](https://www.guidelinecentral.com/guideline/502775/pocket-guide/502776/)
30. [Kapinos and Louis (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9969906/)
31. [Kapinos and Louis (2025)](https://pubmed.ncbi.nlm.nih.gov/39396507/)
32. [Kellner et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5739080/)
33. [Kratovil et al. (2026)](https://tremorjournal.org/articles/10.5334/tohm.1229)
34. [Li et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30589951/)
35. [Lin et al. (2025)](https://tremorjournal.org/articles/10.5334/tohm.1060)
36. [Louis and Ottman (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4137360/)
37. [Matthews et al. (2023)](https://onlinelibrary.wiley.com/doi/epdf/10.1002/acn3.51735)
38. [Morgan et al. (2017)](https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2017.00396/full)
39. [Mukherjee and Pandey (2025)](https://movementdisorders.onlinelibrary.wiley.com/doi/abs/10.1002/mdc3.70147)
40. [Okelberry et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38538475/)
41. [Olhaye et al. (2022a)](https://praxismedicines.com/wp-content/uploads/2023/09/Olhaye-et-al_MDS2022_944-221_Abstract-951_QRcode.pdf)
42. [Olhaye et al. (2022b)](https://www.mdsabstracts.org/abstract/a-phase-2-clinical-trial-evaluating-the-efficacy-safety-tolerability-and-pharmacokinetics-of-prax-944-in-adults-with-essential-tremor/)
43. [Ondo et al. (2025)](https://jamanetwork.com/journals/jamaneurology/article-abstract/2840156)
44. [Pahwa et al. (2024)](https://tremorjournal.org/articles/10.5334/tohm.973)
45. [Papapetropoulos et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33764619/)
46. [Petrou (2026)](https://praxismedicines.com/aan2026-s11-004/)
47. [Praxis Precision Medicines (2021)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-2)
48. [Praxis Precision Medicines AAN 2026 Annual Meeting page (2026)](https://praxismedicines.com/2026-aan-annual-meeting/)
49. [Praxis Precision Medicines Breakthrough Therapy Designation announcement (2025)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-fda-has-granted/)
50. [Praxis Precision Medicines earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/08/13/praxis-prax-q2-2026-earnings-call-transcript/)
51. [Praxis Precision Medicines Essential1 randomized withdrawal results announcement (2023)](https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-data-randomized)
52. [Praxis Precision Medicines Essential1 topline results announcement (2023)](https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-topline-results-essential1)
53. [Praxis Precision Medicines Essential3 topline results announcement (2025)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-topline-results-1)
54. [Praxis Precision Medicines Essential3 update announcement (2025)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-provides-update-essential3-and)
55. [Praxis Precision Medicines Expanded Access Policy](https://praxismedicines.com/eap/)
56. [Praxis Precision Medicines first quarter 2026 results announcement (2026)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-19)
57. [Praxis Precision Medicines fourth quarter and full-year 2025 results announcement (2026)](https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-18)
58. [Praxis Precision Medicines NDA acceptance announcement (2026)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-fda-acceptance-new-drug)
59. [Praxis Precision Medicines pre-NDA meeting announcement (2025)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-pre-nda-meeting)
60. [Praxis Precision Medicines second quarter 2026 results announcement (2026)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-20)
61. [Praxis Precision Medicines third quarter 2023 results announcement (2023)](https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-10)
62. [Praxis Precision Medicines third quarter 2026 results announcement (2026)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-21)
63. [Rajput et al. (1984)](https://pmc.ncbi.nlm.nih.gov/articles/PMC1027820/)
64. [Ravikumar et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28370272/)
65. [Scott et al. (2022)](https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.28969)
66. [Shih et al. (2024)](https://tremorjournal.org/articles/10.5334/tohm.886)
67. [Shtilbans et al. (2026)](https://praxismedicines.com/aan2026-17-003/)
68. [Song et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8035980/)
69. [Sun et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13080778/)
70. [Tringham et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22344687/)
71. [Tröster et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16103000/)
72. [Vetterick et al. (2022)](https://link.springer.com/content/pdf/10.1007/s12325-022-02318-8.pdf?pdf=button)
73. [Zappia et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/22886006/)
74. [Zesiewicz et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3208950/)
75. [Zhang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11533039/)
76. [Zhao et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31766050/)
77. [Zhao et al. (2024)](https://www.nature.com/articles/s41586-024-07414-z)

## Related pages
- [Ulixacaltamide: Essential tremor](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor.md)
- [Ulixacaltamide in Essential tremor: Terms and abbreviations](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/terms-and-abbreviations.md)
- [Ulixacaltamide: Essential tremor](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/executive-summary.md)
- [Ulixacaltamide in Essential tremor: Product information and disease description](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/product-information-and-disease-description.md)
- [Ulixacaltamide in Essential tremor: Clinical evidence](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/clinical-evidence.md)
- [Ulixacaltamide in Essential tremor: Economic information and modeling report](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/economics) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/economics.md)
- [Ulixacaltamide in Essential tremor: prevalence by geography](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/prevalence) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/prevalence.md)
- [Ulixacaltamide in Essential tremor: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/cost-effectiveness-analyses.md)
